Tanzer, M C
Matti, I
Hildebrand, J M
Young, S N
Wardak, A
Tripaydonis, A
Petrie, E J
Mildenhall, A L
Vaux, D L
Vince, J E
Czabotar, P E
Silke, J
Murphy, J M
Article History
Received: 14 September 2015
Revised: 26 November 2015
Accepted: 2 December 2015
First Online: 12 February 2016
Competing interests
: JS is a member of the Scientific Advisory Board of TetraLogic Pharmaceuticals Corporation. JMM co-leads a programme funded by Catalyst Therapeutics Pty Ltd and the Walter and Eliza Hall Institute to develop necroptosis inhibitors. The remaining authors declare no conflict of interest.